Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Amanda B. Cooper, Abhishek D. Parmar, Taylor S. Riall, Bruce L. Hall, Matthew H G Katz, Thomas A. Aloia, Henry A. Pitt

    Research output: Contribution to journalArticle

    41 Citations (Scopus)

    Abstract

    Introduction: The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described.

    Methods: Data from the NSQIP Pancreatectomy Demonstration Project (11/2011 to 12/2012) was used to identify patients with pancreatic adenocarcinoma who did and did not receive neoadjuvant therapy. Neoadjuvant therapy was classified as chemotherapy alone or radiation ± chemotherapy. Outcomes in the neoadjuvant vs. surgery first groups were compared.

    Results: Of 1,562 patients identified at 43 hospitals, 199 (12.7 %) received neoadjuvant therapy (99 chemotherapy alone and 100 radiation ± chemotherapy). Preoperative biliary stenting (57.9 vs. 44.7 %, p = 0.0005), vascular resection (41.5 vs. 17.3 %, p < 0.0001), and open resections (94.0 vs. 91.4 %, p = 0.008) were more common in the neoadjuvant group. Thirty-day mortality (2.0 vs. 1.5 %, p = 0.56) and postoperative morbidity rates (56.3 vs. 52.8 %, p = 0.35) were similar between groups. Neoadjuvant therapy patients had fewer organ space infections (3.0 vs. 10.3 %, p = 0.001), and neoadjuvant radiation patients had fewer pancreatic fistulas (7.3 vs. 15.4 %, p = 0.03).

    Conclusions: Despite evidence for more extensive disease, patients receiving neoadjuvant therapy did not experience more complications. Neoadjuvant radiation was associated with lower pancreatic fistula rates. These data provide evidence against higher postoperative complication rates in patients with pancreatic cancer who are treated with neoadjuvant therapy.

    Original languageEnglish (US)
    Pages (from-to)80-87
    Number of pages8
    JournalJournal of Gastrointestinal Surgery
    Volume19
    Issue number1
    DOIs
    StatePublished - 2014

    Fingerprint

    Neoadjuvant Therapy
    Adenocarcinoma
    Morbidity
    Mortality
    Radiation
    Pancreatic Fistula
    Drug Therapy
    Pancreatectomy
    Pancreatic Neoplasms
    Blood Vessels
    Infection

    Keywords

    • Neoadjuvant chemoradiation
    • Neoadjuvant chemotherapy
    • Pancreatectomy
    • Pancreatic fistula

    ASJC Scopus subject areas

    • Surgery
    • Gastroenterology

    Cite this

    Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates? / Cooper, Amanda B.; Parmar, Abhishek D.; Riall, Taylor S.; Hall, Bruce L.; Katz, Matthew H G; Aloia, Thomas A.; Pitt, Henry A.

    In: Journal of Gastrointestinal Surgery, Vol. 19, No. 1, 2014, p. 80-87.

    Research output: Contribution to journalArticle

    Cooper, Amanda B. ; Parmar, Abhishek D. ; Riall, Taylor S. ; Hall, Bruce L. ; Katz, Matthew H G ; Aloia, Thomas A. ; Pitt, Henry A. / Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?. In: Journal of Gastrointestinal Surgery. 2014 ; Vol. 19, No. 1. pp. 80-87.
    @article{bbf362d52d2d4fb3b1c6ac775e52f268,
    title = "Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?",
    abstract = "Introduction: The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described.Methods: Data from the NSQIP Pancreatectomy Demonstration Project (11/2011 to 12/2012) was used to identify patients with pancreatic adenocarcinoma who did and did not receive neoadjuvant therapy. Neoadjuvant therapy was classified as chemotherapy alone or radiation ± chemotherapy. Outcomes in the neoadjuvant vs. surgery first groups were compared.Results: Of 1,562 patients identified at 43 hospitals, 199 (12.7 {\%}) received neoadjuvant therapy (99 chemotherapy alone and 100 radiation ± chemotherapy). Preoperative biliary stenting (57.9 vs. 44.7 {\%}, p = 0.0005), vascular resection (41.5 vs. 17.3 {\%}, p < 0.0001), and open resections (94.0 vs. 91.4 {\%}, p = 0.008) were more common in the neoadjuvant group. Thirty-day mortality (2.0 vs. 1.5 {\%}, p = 0.56) and postoperative morbidity rates (56.3 vs. 52.8 {\%}, p = 0.35) were similar between groups. Neoadjuvant therapy patients had fewer organ space infections (3.0 vs. 10.3 {\%}, p = 0.001), and neoadjuvant radiation patients had fewer pancreatic fistulas (7.3 vs. 15.4 {\%}, p = 0.03).Conclusions: Despite evidence for more extensive disease, patients receiving neoadjuvant therapy did not experience more complications. Neoadjuvant radiation was associated with lower pancreatic fistula rates. These data provide evidence against higher postoperative complication rates in patients with pancreatic cancer who are treated with neoadjuvant therapy.",
    keywords = "Neoadjuvant chemoradiation, Neoadjuvant chemotherapy, Pancreatectomy, Pancreatic fistula",
    author = "Cooper, {Amanda B.} and Parmar, {Abhishek D.} and Riall, {Taylor S.} and Hall, {Bruce L.} and Katz, {Matthew H G} and Aloia, {Thomas A.} and Pitt, {Henry A.}",
    year = "2014",
    doi = "10.1007/s11605-014-2620-3",
    language = "English (US)",
    volume = "19",
    pages = "80--87",
    journal = "Journal of Gastrointestinal Surgery",
    issn = "1091-255X",
    publisher = "Springer New York",
    number = "1",

    }

    TY - JOUR

    T1 - Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

    AU - Cooper, Amanda B.

    AU - Parmar, Abhishek D.

    AU - Riall, Taylor S.

    AU - Hall, Bruce L.

    AU - Katz, Matthew H G

    AU - Aloia, Thomas A.

    AU - Pitt, Henry A.

    PY - 2014

    Y1 - 2014

    N2 - Introduction: The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described.Methods: Data from the NSQIP Pancreatectomy Demonstration Project (11/2011 to 12/2012) was used to identify patients with pancreatic adenocarcinoma who did and did not receive neoadjuvant therapy. Neoadjuvant therapy was classified as chemotherapy alone or radiation ± chemotherapy. Outcomes in the neoadjuvant vs. surgery first groups were compared.Results: Of 1,562 patients identified at 43 hospitals, 199 (12.7 %) received neoadjuvant therapy (99 chemotherapy alone and 100 radiation ± chemotherapy). Preoperative biliary stenting (57.9 vs. 44.7 %, p = 0.0005), vascular resection (41.5 vs. 17.3 %, p < 0.0001), and open resections (94.0 vs. 91.4 %, p = 0.008) were more common in the neoadjuvant group. Thirty-day mortality (2.0 vs. 1.5 %, p = 0.56) and postoperative morbidity rates (56.3 vs. 52.8 %, p = 0.35) were similar between groups. Neoadjuvant therapy patients had fewer organ space infections (3.0 vs. 10.3 %, p = 0.001), and neoadjuvant radiation patients had fewer pancreatic fistulas (7.3 vs. 15.4 %, p = 0.03).Conclusions: Despite evidence for more extensive disease, patients receiving neoadjuvant therapy did not experience more complications. Neoadjuvant radiation was associated with lower pancreatic fistula rates. These data provide evidence against higher postoperative complication rates in patients with pancreatic cancer who are treated with neoadjuvant therapy.

    AB - Introduction: The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described.Methods: Data from the NSQIP Pancreatectomy Demonstration Project (11/2011 to 12/2012) was used to identify patients with pancreatic adenocarcinoma who did and did not receive neoadjuvant therapy. Neoadjuvant therapy was classified as chemotherapy alone or radiation ± chemotherapy. Outcomes in the neoadjuvant vs. surgery first groups were compared.Results: Of 1,562 patients identified at 43 hospitals, 199 (12.7 %) received neoadjuvant therapy (99 chemotherapy alone and 100 radiation ± chemotherapy). Preoperative biliary stenting (57.9 vs. 44.7 %, p = 0.0005), vascular resection (41.5 vs. 17.3 %, p < 0.0001), and open resections (94.0 vs. 91.4 %, p = 0.008) were more common in the neoadjuvant group. Thirty-day mortality (2.0 vs. 1.5 %, p = 0.56) and postoperative morbidity rates (56.3 vs. 52.8 %, p = 0.35) were similar between groups. Neoadjuvant therapy patients had fewer organ space infections (3.0 vs. 10.3 %, p = 0.001), and neoadjuvant radiation patients had fewer pancreatic fistulas (7.3 vs. 15.4 %, p = 0.03).Conclusions: Despite evidence for more extensive disease, patients receiving neoadjuvant therapy did not experience more complications. Neoadjuvant radiation was associated with lower pancreatic fistula rates. These data provide evidence against higher postoperative complication rates in patients with pancreatic cancer who are treated with neoadjuvant therapy.

    KW - Neoadjuvant chemoradiation

    KW - Neoadjuvant chemotherapy

    KW - Pancreatectomy

    KW - Pancreatic fistula

    UR - http://www.scopus.com/inward/record.url?scp=84939465687&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84939465687&partnerID=8YFLogxK

    U2 - 10.1007/s11605-014-2620-3

    DO - 10.1007/s11605-014-2620-3

    M3 - Article

    VL - 19

    SP - 80

    EP - 87

    JO - Journal of Gastrointestinal Surgery

    JF - Journal of Gastrointestinal Surgery

    SN - 1091-255X

    IS - 1

    ER -